Novartis Venture Fund Overview

  • Investor Type
  • Venture Capital

  • Status
  • Active

  • Professionals
  • 10

Professionals
  • Investments
  • 324

  • Portfolio
  • 43

  • Exits
  • 161

Exits

Novartis Venture Fund General Information

Description

Founded in 1996, Novartis Venture Fund is a corporate venture capital arm of Novartis headquartered in Basel, Switzerland. The firm has a regional office in Cambridge, Massachusetts. The firm seeks to invest in the life sciences, oncology, biotechnology, and digital health sectors.

Contact Information

Website
www.nvfund.com
Year Founded
1996
Investor Status
Actively Seeking New Investments
Trade Association
New England Venture Capital Association (NEVCA)
National Venture Capital Association (NVCA)
Primary Investor Type
Corporate Venture Capital
Other Investor Types
Growth/Expansion
Primary Office
  • Postfach
  • 4002 Basel
  • Switzerland
+41 061 000 00 00

Novartis Venture Fund Investments (324)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Enterprise Therapeutics 09-Mar-2022 Later Stage VC 00.000 Drug Discovery Generating Revenue 0000 000000000 00
000000 28-Feb-2022 000000000000 00.000 Other Healthcare Technology Systems Clinical Trials - Phase 2
000000 000 16-Feb-2022 00000 00000 000.00 Drug Discovery Generating Revenue 0000 0000000 00
000000000 14-Feb-2022 00000 00000 000.00 Drug Discovery Clinical Trials - Phase 1 00000000 00000 00.0
0000000 000 14-Jan-2022 00000 00000 00000 Drug Discovery Generating Revenue 000000 0000000000
0000000 23-Dec-2021 00000 00000 00000 Drug Discovery Generating Revenue 0000000 00000000000000 00.0
0000000 0000000000 23-Nov-2021 0000 00000 000.00 Biotechnology Startup 0000000 00000000000000 00.0
000 000000000000 04-Oct-2021 00000 00000 000.00 Drug Discovery Generating Revenue 00000 000000 00.0
Expansion Therapeutics 29-Sep-2021 Later Stage VC 0000 Drug Discovery Generating Revenue 00000 00000 00.0
Immunitas Therapeutics 18-Aug-2021 Early Stage VC 0000 Drug Discovery Clinical Trials - General 00000 00000 00.0
You’re viewing 10 of 324 investments. Get the full list »

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novartis Venture Fund Exits (161)

Company Name Exit Date Exit Type Exit Size
Viamet Pharmaceuticals Holdings 10-Jan-2022 Out of Business
0000000 000000 13-Dec-2021 000000000000000000 00000
00000000 000000 01-Nov-2021 000000000000000000 00000
000000 0000000 21-Sep-2021 000000000000000000
000000000 02-Sep-2021 0000000 000000 000.00
000000 26-Aug-2021 000000000000000000
00000000 000000000 26-Aug-2021 0000000 000000 00000
0000000 01-Aug-2021 0000000000: 000000
Genedata 01-Aug-2021 Secondary Transaction - Private
Rani Therapeutics 30-Jul-2021 IPO 000.00
You’re viewing 10 of 161 exits. Get the full list »

Novartis Venture Fund Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Novartis Venture Fund Team (28)

Name Title Deals Funds Boards Office
Anja König Ph.D Global Head 00 0 0 Basel, Switzerland
Bart Dzikowski JD Managing Director and Head of Transactions & Legal 0 0 0 Basel, Switzerland
Aaron Nelson Ph.D Managing Director 0 0 0 Cambridge, MA
Beat Steffen MD Managing Director 0 0 0 Basel, Switzerland
Florian Muellershausen Ph.D Managing Director 0 0 Basel, Switzerland
You’re viewing 5 of 28 team members. Get the full list »

Novartis Venture Fund Co-Investors (195)

Name With Exits Lead Partner Series Industry
Forbion 5 0 0 Series chart Industry bar
Johnson & Johnson Innovation - JJDC 0 0 0 Series chart Industry bar
M Ventures 0 0 0 Series chart Industry bar
Novo Holdings 0 0 0 Series chart Industry bar
OrbiMed 0 0 0 Series chart Industry bar
You’re viewing 5 of 195 co-investors. Get the full list »